while drugmaker dr reddy's laboratories' q3 earnings were slightly above the street's estimates, the highlight of the show was the declining revenue contribution from revlimid, which also weighed on margins. with revlimid, the blockbuster cancer drug and a key growth driver for dr reddy's in recent years, approaching its patent expiry in january 2026, concerns about potential revenue loss are mounting.the concerns also triggered a 6 percent fall

following a sudden rise, benchmark indices nifty and sensex erased all gains to trade largely flat on the bourses on january 21 following a sharp downturn in ph

shares of mankind pharma plunged nearly 6 percent on january 24, weighed down by a fall in the company's october-december net profit. the company's bottom line

shares of telecommunications player indus tower gained two percent in the morning session on january 24, after its reporting better-than-expected earnings for t

shares of cyient took a strong beating on january 24, plummeting over 19 percent amid a slew of negative triggers for the company. firstly, the it company's wea

the indian it sector is at a crossroads, caught between the promise of long-term growth and the uncertainties of a rapidly shifting global landscape. as the nif

the nifty 50 outperformed the bank nifty, rising two-tenths of a percent on january 23 with the continuation of its upward journey for the second consecutive se

the nifty 50 extended gains amid range-bound trade, rising 0.2 percent on january 23, but has still been broadly moving in the range of 23,000-23,400 since last

the benchmark indices maintained their upward journey for another session, rising 0.2 percent amid range-bound trading on january 23, with positive market bread

let's catch up on the latest news from the stock market. from significant investments to major deals, quarterly earnings, and order wins, here’s a quick look